Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • BIOBUSINESS BRIEFS

The small-molecule antibiotics pipeline: 2014–2018

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature Reviews Drug Discovery 18, 739 (2019)

doi: https://doi.org/10.1038/d41573-019-00130-8

Acknowledgement

The authors acknowledge Wes Kim for reviewing the analysis, and editing and advising on the direction of the article.

Supplementary Information

  1. Supplementary Box S1

Competing Interests

L.S. has been paid for consulting in the last 3 years by CARB-X, IMI and Debiopharm.

Subjects

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links